Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient

Some Suggestions from PK/PD Principles to Contain Resistance in the Clinical Setting—Focus on ICU Patients and Gram-Negative Strains

(2020) Chiara Adembri et al.   Antibiotics-Basel

Augmented Renal Clearance

(2019) Aaron M. Cook et al.   PHARMACOTHERAPY

What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review

(2019) Chandra Datta Sumi et al.   CLINICAL PHARMACOKINETICS

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

(2018) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Individualising Therapy to Minimize Bacterial Multidrug Resistance

(2018) A. J. Heffernan et al.   DRUGS

In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment

(2018) Paolo Gaibani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups

(2018) Jianguo Li et al.   CTS-Clinical and Translational Science

Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

(2017) Isabelle K. Delattre et al.   Expert Review of Anti-Infective Therapy

Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria

(2017) Vincent H. Tam et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies

(2015) Henri Merdjan et al.   CLINICAL DRUG INVESTIGATION

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

(2013) George G. Zhanel et al.   DRUGS